CIK 0001549595 · Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 270838048
- Phone
- (415) 660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-31 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −100 | $20.48 | $2K | 32,538 |
| 2025-01-31 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −223 | 53,763 | ||
| 2025-01-31 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,537 | 0 | ||
| 2025-01-30 | Ring Christine Chief Legal Officer | Option exercise | +1,924 | 30,008 | ||
| 2025-01-30 | Ring Christine Chief Legal Officer | Option exercise | +2,000 | 32,008 | ||
| 2025-01-30 | Ring Christine Chief Legal Officer | Option exercise | +3,750 | 35,758 | ||
| 2025-01-30 | Ring Christine Chief Legal Officer | Sale | −2,929 | $19.81 | $58K | 32,829 |
| 2025-01-30 | Ring Christine Chief Legal Officer | Sale | −291 | $20.33 | $6K | 32,538 |
| 2025-01-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −1,924 | 7,697 | ||
| 2025-01-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −2,000 | 10,000 | ||
| 2025-01-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −3,750 | 33,750 | ||
| 2025-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +3,207 | 53,877 | ||
| 2025-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +2,000 | 55,877 | ||
| 2025-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +3,750 | 59,627 | ||
| 2025-01-30 | Hansen Gwenn Chief Scientific Officer | Sale | −3,357 | $19.81 | $66K | 56,270 |
| 2025-01-30 | Hansen Gwenn Chief Scientific Officer | Sale | −333 | $20.33 | $7K | 55,937 |
| 2025-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,207 | 12,827 | ||
| 2025-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −2,000 | 10,000 | ||
| 2025-01-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,750 | 33,750 | ||
| 2025-01-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,886 | 36,610 |
Page 15 of 20 · 381 trades